RE:Follow this thought with more.. They need to give that webcast some legs, give that presentation to a few other conferences and keep pushing -I agree. Getting a thorough LSA report would go nicely with that pitch - one with more science and actual commercial aspects.
I also wonder about hitting a dose limiting toxicity. One slide shows there was essentially no free doxorubicin accumulating in the healthy ovarian data and we know eutropenia has not been observed yet after 6 doses. So what happens if they end up with no DLTs and the max dose is something like 2-5x the regular chemo dose or even more? I guess you'd use that dose and potentially help efficacy. Crazy question but the lab science points to them being able to use a much higher dose in a safe manner.
scarlet1967 wrote: Attendance in conferences, don't let the excitement fade away. I have a feeling that the company won't release oncology trial specific information until the end of part1 of phase1 even so they might had/have that information.
They want to wait for DLT and possibly MTD to be confirmed by more cohorts and I don't buy the notion they won't get updated by cancer centre/centres. So we have a little time vacuum between now and late summer. Unless they have some NASH news they should get out there and keep promoting. This webinar didn't address the commercial side of the program despite many asked that question. Now prepare a retail
oriented pitch and attend retail platforms. Today over 280k shares were traded in Nasdaq, one of the highest daily volumes in weeks, the short volume spiked to over 26% which is over the average in the last few weeks too so THTX needs to stop this little shorting game every time they announce news by getting out there and convince the investors this is a good ROI in any time span as they will soon announce NASH protocol followed by oncology results followed by NASH trial..